top of page
image.png

RETICAD helps identify patients with retina disease who may benefit from treatment

This patent-protected software measures critical hallmarks of retinal diseases caused by diabetes and aging, including vascular leakage and non-perfusion.

​By doing so, it allows the identification of patients who may benefit from specific interventions targeting these disease hallmarks.

RETICAD's measures of leakage and perfusion

image.png

Vascular leakage before treatment

image.png

Tissue perfusion before treatment

image.png

Reduced vascular leakage after treatment

image.png

0.16

image.png

Leakage rate

0

18

image.png

Perfusion rate

0

Improved tissue perfusion after treatment

image.png

GenFA makes detection of vascular leakage and non-perfusion highly accessible

This patent-pending AI software makes the test for visualizing leakage and non-perfusion (Fluorescein Angiography) simple and highly accessible, by eliminating the need for dye injection.

PUBLICATIONS

  1. Quantitative Fluorescein Angiography Biomarkers in Diabetic Macular Edema.
    Retina. 2025.
     

  2. Dye-free fluorescein angiography and retinal leakage analysis.
    48th Annual Meeting of the Macula Society. 2025. Charlotte Harbor, FL, USA.
     

  3. RETICAD: A tool for generating dye-free fluorescein angiography and quantifying retinal disease activity.
    ARVO annual meeting. 2024. Seattle,WA, USA.
     

  4. RETICAD: Quantitative Analysis of Treatment Response in Eyes with Retinal Vein Occlusion.
    ARVO annual meeting. 2024. Seattle,WA, USA.
     

  5. Prediction of Visual Acuity Response to Ranibizumab in Age-Related Macular Degeneration Using Artificial Intelligence-Based Analysis of Fluorescein Angiography.
    ARVO annual meeting. 2024. Seattle,WA, USA.
     

  6. RETICAD: an artificial intelligence (AI) tool for generating dye free fluorescein angiography. 
    47th Annual Meeting of the Macula Society. 2024. Palm Springs, CA, USA.
     

  7. Mechanisms of blood-retinal barrier disruption related to intraocular inflammation and malignancy.
    Prog Retin Eye Res. 2024
     

  8. Association of Intravenous Fluorescein Angiography and Adaptive Optics Imaging in Diabetic Retinopathy.
    Retina. 2024.
     

  9. Artificial intelligence-based extraction of quantitative ultra-widefield fluorescein angiography parameters in retinal vein occlusion.
    Can J Ophthalmol. 2024
     

  10. Artificial Intelligence-Enhanced Analysis of Retinal Vasculature in Age-Related Macular Degeneration.
    Retina. 2024.
     

  11. An Algorithm for Detecting Leaky Retinal Microaneurysms.
    ARVO annual meeting. 2023. New Orleans, LA, USA.
     

  12. An Automated Tool for Quantitative Assessment of Retinal Vasculopathy.
    ARVO annual meeting. 2023. New Orleans, LA, USA.
     

  13. A fluorescein angiography-based computer-aided algorithm for assessing the retinal vasculature in diabetic retinopathy.
    Eye. 2023.
     

  14. Angiographic evidence of proliferative retinopathy predicts neuropsychiatric morbidity in diabetic patients.
    Psychoneuroendocrinology. 2016.
     

  15. Retinal Fluorescent Angiography Predicts Blood-Brain Barrier Damage and Neuropsychiatric Morbidity in Diabetic Patients.
    Mediterranean Neuroscience Society 5th Meeting. 2015. Santa Margherita di Pula, Sardinia, Italy.
     

  16. Novel fluorescein angiography-based computer-aided algorithm for assessment of retinal vessel permeability.
    PLoS One. 2013.

EMAGIX

1344 Summer Street,
Halifax, NS, ​B3H 0A8, Canada
​info@emagix.ca​

©2025 EMAGIX Inc. All rights reserved

bottom of page